Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Amlodipine: adverse event reports

All products with this active ingredient · not in an FDA-approved animal drug

722reports naming this ingredient, 2012–20260.1% of all reports · about 51 a year
122reports, 12 months to March 2026158 in the 12 months before
52.2%classed serious, as reportedof 718 reports stating it
15.9%record death or euthanasia, as reported115 reports
50.1%of reports concern cats0.2% of all cat reports

Between January 2012 and March 2026 FDA received 722 adverse event reports listing a drug with amlodipine as the recorded active ingredient. It is not the active ingredient of an FDA-approved animal drug; it reaches animals through human-label or compounded products.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 122 reports named it, down 23% from 158 in the 12 months before. Recent months are provisional: fDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 51 reports a year and 0.1% of all 1,357,245 reports (0.2% of all cat reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The most frequently coded terms are lethargy (17.7%), vomiting (14.5%) and diarrhoea (12.9%). A report can list several signs, so shares add to more than 100%; 804 different terms appear across these reports.

50.1% of reports concern cats. Not every report describes illness: 10.9% were filed wholly or partly as lack of expected effectiveness. Of reports that state seriousness, 52.2% were classed as serious, and 15.9% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog168 · peak 9
Apr 2021: 2May 2021: 3Jun 2021: 2Jul 2021: 1Aug 2021: 2Sep 2021: 2Nov 2021: 1Dec 2021: 2Jan 2022: 2Feb 2022: 1Mar 2022: 6Apr 2022: 2May 2022: 3Jul 2022: 2Aug 2022: 1Oct 2022: 1Nov 2022: 1Dec 2022: 2Jan 2023: 1Feb 2023: 4Mar 2023: 1Apr 2023: 1May 2023: 2Jun 2023: 1Jul 2023: 2Aug 2023: 1Sep 2023: 1Oct 2023: 1Nov 2023: 9Dec 2023: 7Jan 2024: 1Feb 2024: 4Mar 2024: 2Apr 2024: 4May 2024: 9Jun 2024: 6Jul 2024: 4Aug 2024: 5Sep 2024: 4Oct 2024: 8Nov 2024: 6Dec 2024: 2Jan 2025: 8Feb 2025: 3Mar 2025: 4Apr 2025: 2May 2025: 6Jun 2025: 4Jul 2025: 3Oct 2025: 3Nov 2025: 3Dec 2025: 1Jan 2026: 4Feb 2026: 4Mar 2026: 12022202320242025
Cat287 · peak 15
Apr 2021: 2May 2021: 2Jun 2021: 3Aug 2021: 1Sep 2021: 2Oct 2021: 1Nov 2021: 1Dec 2021: 1Jan 2022: 2May 2022: 1Aug 2022: 2Sep 2022: 2Oct 2022: 3Nov 2022: 3Dec 2022: 5Jan 2023: 10Feb 2023: 4Mar 2023: 5Apr 2023: 5May 2023: 3Jun 2023: 5Jul 2023: 4Aug 2023: 4Sep 2023: 2Oct 2023: 6Nov 2023: 3Dec 2023: 7Jan 2024: 7Feb 2024: 7Mar 2024: 4Apr 2024: 7May 2024: 7Jun 2024: 7Jul 2024: 15Aug 2024: 8Sep 2024: 10Oct 2024: 11Nov 2024: 2Dec 2024: 6Jan 2025: 5Feb 2025: 6Mar 2025: 8Apr 2025: 11May 2025: 10Jun 2025: 6Jul 2025: 6Aug 2025: 7Sep 2025: 4Oct 2025: 10Nov 2025: 6Dec 2025: 9Jan 2026: 8Feb 2026: 8Mar 2026: 32022202320242025
Horse0 · peak 1
2022202320242025
Other17 · peak 2
Apr 2021: 1May 2021: 1Jun 2021: 1Jul 2021: 1Jun 2022: 2Apr 2023: 1Jun 2023: 1Oct 2023: 1Dec 2023: 1Feb 2024: 1Aug 2024: 1Jan 2025: 1Mar 2025: 1Apr 2025: 1Sep 2025: 1Nov 2025: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

0741482012: 3020122013: 2220132014: 2120142015: 2520152016: 3320162017: 2320172018: 3520182019: 3020192020: 2320202021: 4020212022: 4120222023: 9320232024: 14820242025: 13020252026: 282026

2026 covers reports received through March 2026 only.

Signs listed in reports

share of amlodipine reports listing the termall cat reports

  1. Lethargy[unusually tired or inactive]17.7%128
  2. Vomiting14.5%105
  3. Diarrhoea[diarrhea]12.9%93
  4. Death by euthanasia[the animal was euthanized]11.1%80
  5. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]9.3%67
  6. Lack of efficacy - NOS[the product did not have the expected effect]8.3%60
  7. Anorexia[not eating]7.9%57
  8. Elevated creatinine[a kidney value above the normal range]7.5%54
  9. Other abnormal test result NOS[abnormal laboratory result, type not specified]6.6%48
  10. Ataxia[unsteady, uncoordinated movement]5.8%42
  11. Anaemia NOS[low red blood cell count]5.7%41
  12. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]5.4%39
  13. Hypertension[high blood pressure]5.4%39
  14. Behavioural disorder NOS[behaviour change, type not specified]4.7%34
  15. Death4.7%34
  16. Seizure NOS[seizure, type not specified]4.7%34
  17. Hyperkalaemia[high blood potassium]4.6%33
  18. Hyperglycaemia[high blood sugar]4.4%32
  19. Elevated symmetrical dimethylarginine (SDMA)[a kidney value above the normal range]3.9%28
  20. Weakness3.6%26
  21. Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]3.2%23
  22. Accidental exposure[exposure that was not intended]3%22
  23. Hyperphosphataemia[high blood phosphate]3%22
  24. Vocalisation[crying out or unusual noise]3%22

Top 30 of 804 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal21.1%152
Recovered with Sequela0.8%6
Ongoing35.9%259
Died5.3%38
Euthanized10.8%78
Outcome Unknown26.5%191

What kind of report it was

Safety issue87.5%632
Lack of expected effectiveness4.7%34
Both safety and lack of expected effectiveness6.2%45
Manufacturing or product defect1.2%9
Other0.3%2

Coloured bar: reports naming amlodipine. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Cat50.1%362
Dog45.2%326
Human exposure4.6%33

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year0.1%1
1 to 3 years0.8%6
4 to 7 years5.3%38
8 to 11 years18.6%134
12 years and over72.2%521
Age not given3%22

Weight of the animal

Under 5 kg (11 lb)42.5%307
5 to 9.9 kg (11–22 lb)25.1%181
10 to 24.9 kg (22–55 lb)13%94
25 to 44.9 kg (55–99 lb)8%58
45 kg and over (99 lb+)4.6%33
Weight not given6.8%49

Route of administration stated in reports: oral (380), topical (3), transdermal (3), other (1), subcutaneous (1).

In context

MeasureAmlodipineAll cat reportsAll reports
Reports722148,0801,357,245
Share of that pool's reports naming this drug—0.2%0.1%
Classed serious, of reports stating it52.2%35.6%38.6%
Death or euthanasia recorded, per 1,000 reports159.39563.8
Filed as lack of expected effectiveness (wholly or partly)10.9%—23%
Top term, share of reportsLethargy 17.7%9.7%—

This set accounts for 98.8% of all reports naming amlodipine, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

The Green Book lists no approved animal drug with these ingredients. Reports reach FDA for human-label and compounded drugs that veterinarians prescribe.

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about amlodipine reports

How many adverse event reports has FDA received for amlodipine?

722 reports record a drug with amlodipine as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 122 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

What signs are reported most often?

lethargy (17.7%), vomiting (14.5%), diarrhoea (12.9%), death by euthanasia (11.1%) and weight loss (10.9%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

cat (50.1%), dog (45.2%) and human exposure (4.6%). Among single-breed animals the most frequent labels are Domestic Shorthair, Domestic Longhair, Domestic Mediumhair and Shih Tzu; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

122 reports in the 12 months to March 2026, down 23% from 158 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that amlodipine harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of amlodipine?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.